Home

Capricor Therapeutics, Inc. - Common Stock (CAPR)

7.8100
-1.2600 (-13.89%)
NASDAQ · Last Trade: Aug 11th, 12:55 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close9.070
Open8.180
Bid7.800
Ask7.810
Day's Range7.810 - 8.337
52 Week Range3.710 - 23.40
Volume1,238,983
Market Cap356.74M
PE Ratio (TTM)-5.701
EPS (TTM)-1.4
Dividend & YieldN/A (N/A)
1 Month Average Volume2,926,604

Chart

About Capricor Therapeutics, Inc. - Common Stock (CAPR)

Capricor Therapeutics is a clinical-stage biotechnology company focused on developing innovative cellular therapeutics to treat rare and chronic diseases. The company primarily works on harnessing the potential of stem cell-derived therapies, with a particular emphasis on cardiac and musculoskeletal conditions. Capricor aims to advance its proprietary technologies through rigorous research and development, striving to bring transformative treatment options to patients with unmet medical needs. By leveraging its expertise and pioneering spirit, Capricor seeks to make significant contributions to the field of regenerative medicine. Read More

News & Press Releases

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 11, 2025
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 11, 2025
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (NASDAQ: CAPR)
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, inclusive.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 11, 2025
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · August 11, 2025
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
NEW YORK, Aug. 10, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · August 10, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (“Capricor” or the “Company”) (NASDAQ: CAPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 9, 2025
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 8, 2025
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 8, 2025
Investors in Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 7, 2025
Investors in Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
NEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 7, 2025
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company.
By Kirby McInerney LLP · Via Business Wire · August 6, 2025
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR
NEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 6, 2025
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Lawsuit - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 6, 2025
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
By Bragar Eagel & Squire · Via GlobeNewswire · August 5, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc.  (“Capricor” or the “Company”) (NASDAQ: CAPR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 5, 2025
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
NEW YORK - August 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 5, 2025
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 5, 2025
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 4, 2025
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 15, 2025 - CAPR
NEW YORK - August 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 4, 2025
CAPRICOR THERAPEUTICS, INC. (NASDAQ: CAPR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Capricor Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
By Bernstein Liebhard LLP · Via GlobeNewswire · August 4, 2025
ROSEN, A LEADING NATIONAL FIRM, Encourages Capricor Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CAPR
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · August 3, 2025
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits
If you purchased or acquired securities in any of the above companies during their class period and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648
By Bragar Eagel & Squire · Via GlobeNewswire · August 2, 2025
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · August 1, 2025
Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - CAPR
NEW YORK - August 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.
Via TheNewswire.com · August 1, 2025
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · August 1, 2025